Amphastar 10-Q: Q3 Revenue Up 8% to $207.6M, EPS $0.87, Gross Margin Slips to 48.0%
AMPH sits 81% above its 52-week low of $16.645.
Summary
Amphastar's Q3 10-Q confirms 8% revenue growth to $207.6M and $0.87 diluted EPS, but gross margin compressed to 48.0% on weaker pricing and IMS remediation costs, with a $12.5M IMS-related backlog disclosed.
Key Events · Earnings and Guidance · AMPH
-
Q3 Revenue Up 8% to $207.6M
Net revenues rose to $207.6M from $191.8M, led by BAQSIMI at $58.8M (up 10%) and Primatene MIST at $31.5M (up 9%); lidocaine jumped 29% to $16.6M while glucagon fell 37% to $8.6M.
-
EPS Nearly Doubles, Margin Compresses
Diluted EPS was $0.87 versus $0.37, helped by a $23.1M litigation provision in the prior-year quarter; gross margin fell to 48.0% from 51.4% on lower average selling prices for BAQSIMI, glucagon and epinephrine multi-dose vials plus higher IMS remediation and facility expansion costs.
-
IMS Warning Letter Creates $12.5M Backlog
Slower product releases during FDA warning-letter remediation at the IMS facility left roughly $12.5M of backlog at September 30, 2026, and management expects manufacturing expenses to keep rising as remediation continues.
-
$100M Lilly Milestone Paid and Capitalized
BAQSIMI's first annual net sales milestone of $175.0M triggered a $100.0M payment to Lilly in Q3, allocated $94.5M to product rights and $5.5M to PP&E and amortized over a 21-year remaining life.
Analysis · AMPH · Life Sciences
The full quarterly report behind this morning's headline reveals the quality of the beat: revenue growth is real, but gross margin fell to 48.0% from 51.4% as BAQSIMI, glucagon and epinephrine multi-dose vials sold at lower average prices, while IMS remediation and facility expansion raised manufacturing costs. The IMS FDA warning letter is now quantified — a $12.5M product backlog at quarter-end from slower releases — and management says manufacturing expense will keep rising as it remediates. Offsetting that, the $100.0M Lilly milestone for hitting BAQSIMI's first annual net sales threshold was paid in Q3 and capitalized ($94.5M to intangibles), so it hits the balance sheet and future amortization rather than the income statement. Cash stands at $204.6M against $620.4M of debt, and buybacks slowed sharply to 21,747 shares for $0.4M in Q3 versus $74.6M across the first nine months.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMPH was trading at $30.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $16.65 to $29.52. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.